Highlights Madrigal Pharmaceuticals, Inc.

Equities

MDGL

US5588681057

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
193.3 ^USD	-0.54%		-8.82%	-16.44%

Apr. 22	BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective	MT
Apr. 22	BofA Securities Starts Madrigal Pharmaceuticals With Underperform Rating, $150 Price Target	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Madrigal Pharmaceuticals Says Rezdiffra Available in US	Apr. 09	MT
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis	Apr. 09	CI
Madrigal plans $500 million fund raising to prepare for NASH drug launch	Mar. 18	RE
Global markets live: Adobe, Ulta Beauty, Intel, Walt Disney, McDonald's...	Mar. 15
Madrigal Shares Leap Premarket on First FDA NASH Green Light	Mar. 15	DJ
Madrigal Pharmaceuticals Wins Accelerated Approval for Rezdiffra From FDA	Mar. 14	DJ
Madrigal Pharmaceuticals, Inc. Announces FDA Approval of Rezdiffra? for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis with Moderate to Advanced Liver Fibrosis	Mar. 14	CI
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis	Mar. 05	CI
Madrigal Pharmaceuticals Q4 Loss Widens	Feb. 28	MT
Madrigal Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Madrigal Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
North American Morning Briefing : Stock Futures -2-	Feb. 27	DJ
Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine	Feb. 08	CI
Sagimet's shares hit new high as fatty liver disease drug shows promise in study	Jan. 22	RE
Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference	Jan. 04	CI
Madrigal Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of Nash with Liver	23-09-13	CI
Madrigal Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Madrigal Seeks FDA Accelerated Approval for NASH With Liver Fibrosis Candidate Resmetirom	23-07-17	MT
Madrigal Pharmaceuticals, Inc. Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of Nash with Liver Fibrosis	23-07-17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Madrigal Pharmaceuticals, Inc.

Equities

MDGL

US5588681057

Highlights

Filters